Selective serotonin reuptake inhibitors in the treatment of depression

A. C. Furman, Charles Nemeroff

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Selective serotonin reuptake inhibitors (SSRIs) comprise a relatively new class of antidepressants that are believed to act largely by blocking serotonin (5-HT) reuptake into presynaptic nerve terminals in the central nervous system. Widely prescribed throughout the world, SSRIs have a much more favourable side-effect profile than tricyclic antidepressants (TCAs) or monoamine oxidase inhibitors (MAOIs), Their efficacy vs. placebo has been well established and, in general, they exhibit comparable efficacy to tricyclic antidepressants. Controversy still exists as to whether the SSRIs are as efficacious as the TCAs in severe depression including melancholia. Differences do exist between the SSRIs in terms of their pharmacokinetic characteristics, inhibition of various hepatic cytochrome P450 isoenzymes, and side-effect profile, though they are better tolerated than TCAs and MAOIs.

Original languageEnglish
Pages (from-to)101-108
Number of pages8
JournalExpert Opinion on Investigational Drugs
Volume5
Issue number1
StatePublished - Jan 1 1996
Externally publishedYes

Fingerprint

Tricyclic Antidepressive Agents
Serotonin Uptake Inhibitors
Depression
Monoamine Oxidase Inhibitors
Serotonin
Presynaptic Terminals
Therapeutics
Depressive Disorder
Cytochrome P-450 Enzyme System
Antidepressive Agents
Isoenzymes
Central Nervous System
Pharmacokinetics
Placebos
Liver

ASJC Scopus subject areas

  • Pharmacology

Cite this

Selective serotonin reuptake inhibitors in the treatment of depression. / Furman, A. C.; Nemeroff, Charles.

In: Expert Opinion on Investigational Drugs, Vol. 5, No. 1, 01.01.1996, p. 101-108.

Research output: Contribution to journalArticle

@article{dd1768b7e0e843e8b9b993eb85b1928c,
title = "Selective serotonin reuptake inhibitors in the treatment of depression",
abstract = "Selective serotonin reuptake inhibitors (SSRIs) comprise a relatively new class of antidepressants that are believed to act largely by blocking serotonin (5-HT) reuptake into presynaptic nerve terminals in the central nervous system. Widely prescribed throughout the world, SSRIs have a much more favourable side-effect profile than tricyclic antidepressants (TCAs) or monoamine oxidase inhibitors (MAOIs), Their efficacy vs. placebo has been well established and, in general, they exhibit comparable efficacy to tricyclic antidepressants. Controversy still exists as to whether the SSRIs are as efficacious as the TCAs in severe depression including melancholia. Differences do exist between the SSRIs in terms of their pharmacokinetic characteristics, inhibition of various hepatic cytochrome P450 isoenzymes, and side-effect profile, though they are better tolerated than TCAs and MAOIs.",
author = "Furman, {A. C.} and Charles Nemeroff",
year = "1996",
month = "1",
day = "1",
language = "English",
volume = "5",
pages = "101--108",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "1",

}

TY - JOUR

T1 - Selective serotonin reuptake inhibitors in the treatment of depression

AU - Furman, A. C.

AU - Nemeroff, Charles

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Selective serotonin reuptake inhibitors (SSRIs) comprise a relatively new class of antidepressants that are believed to act largely by blocking serotonin (5-HT) reuptake into presynaptic nerve terminals in the central nervous system. Widely prescribed throughout the world, SSRIs have a much more favourable side-effect profile than tricyclic antidepressants (TCAs) or monoamine oxidase inhibitors (MAOIs), Their efficacy vs. placebo has been well established and, in general, they exhibit comparable efficacy to tricyclic antidepressants. Controversy still exists as to whether the SSRIs are as efficacious as the TCAs in severe depression including melancholia. Differences do exist between the SSRIs in terms of their pharmacokinetic characteristics, inhibition of various hepatic cytochrome P450 isoenzymes, and side-effect profile, though they are better tolerated than TCAs and MAOIs.

AB - Selective serotonin reuptake inhibitors (SSRIs) comprise a relatively new class of antidepressants that are believed to act largely by blocking serotonin (5-HT) reuptake into presynaptic nerve terminals in the central nervous system. Widely prescribed throughout the world, SSRIs have a much more favourable side-effect profile than tricyclic antidepressants (TCAs) or monoamine oxidase inhibitors (MAOIs), Their efficacy vs. placebo has been well established and, in general, they exhibit comparable efficacy to tricyclic antidepressants. Controversy still exists as to whether the SSRIs are as efficacious as the TCAs in severe depression including melancholia. Differences do exist between the SSRIs in terms of their pharmacokinetic characteristics, inhibition of various hepatic cytochrome P450 isoenzymes, and side-effect profile, though they are better tolerated than TCAs and MAOIs.

UR - http://www.scopus.com/inward/record.url?scp=0030021043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030021043&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 101

EP - 108

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 1

ER -